Coagulopatía y trombosis: similitudes y diferencias entre coronavirus patogénicos
DOI:
https://doi.org/10.23938/ASSN.0885Palabras clave:
Coronavirus., Coagulación., Trombosis., Dimero D., Tromboprofilaxis.Resumen
La coagulopatía asociada a la enfermedad del coronavirus 2019 (COVID-19), causada por el virus SARS-CoV-2, tiene implicaciones pronósticas por ser responsable de alteraciones analíticas, como el aumento de dímero D, y manifestaciones trombóticas, fundamentalmente tromboembolismo venoso, que obligan a estrategias de tromboprofilaxis. En esta revisión se revisan las principales características clínicas de la infección COVID-19 en comparación con otras infecciones por coronavirus, como el síndrome respiratorio agudo grave (SARS) y el síndrome respiratorio de Oriente Medio (MERS), con énfasis en aspectos clínicos, diagnósticos y terapéuticos.
Descargas
Citas
ZHU N, ZHANG D, WANG W, LI X, YANG B, SONG J et al. Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727-733.
HUANG C, WANG Y, LI X, REN L, ZHAO J, HU Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.
GUAN WJ, NI ZY, HU Y, LIANG WH, OU CQ, HE JX et al. Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-1720.
HELMS J, TACQUARD C, SEVERAC F, LEONARD-LORANT I, OHANA M, DELABRANCHE X et al. High risk of thrombosis in severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46: 1089-1098. https://doi.org/10.1007/s00134-020-06062-x
BIKDELI B, MADHAVAN MV, JIMENEZ D, CHUICH T, DREYFUS I, DRIGGIN E et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020; 23: 2950-2973.
TANG N, LI D, WANG X, SUN Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 844-847. https://doi.org/10.1111/jth.14768
HENRY BM, DE OLIVEIRA MHS, BENOIT S, PLEBANI M, LIPPI G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020. https://doi.org/10.1515/cclm-2020-0369
GRALINSKI LE, BANKHEAD A III, JENG S, MENACHERY VD, PROLL S, BELISLE SE et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio 2013; 4. https://doi.org/10.1128/mbio.00271-13
ANTONIAK S, MACKMAN N. Multiple roles of the coagulation protease cascade during virus infection. Blood 2014; 123: 2605-2613. https://doi.org/10.1182/blood-2013-09-526277
SUBRAMANIAM S, SCHARRER I. Procoagulant activity during viral infections. Front Biosci 2018; 23: 1060-1081. https://doi.org/10.2741/4633
GUPTA N, ZHAO YY, EVANS CE. The stimulation of thrombosis by hypoxia. Thromb Res 2019; 181: 77-83.
PÁRAMO JA. Neutrophils as instigators of thrombosis: beyond antimicrobial protection. Rev Clin Esp 2020. https://doi.org/10.1016/j.rce.2019.11.01
GIANNIS D, ZIOGAS IA, GIANNI P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 2020; 127: 104362. https://doi.org/10.1016/j.jcv.2020.104362.
YIN S, HUANG M, LI D, TANG N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis 2020. https://doi.org/10.1007/s11239-020-02105-8.
TANG N, BAI H, CHEN X, GONG J, LI D, SUN Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18: 1094-1099. https://doi.org/10.1111/jth.14817
NICHOLLS JM, POON LL, LEE KC, NG WF, LAI ST, LEUNG CY et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003; 361: 1773-1778.
CHONG PY, CHUI P, LING AE, FRANKS TJ, TAI DY, LEO YS et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med 2004; 128: 195-204.
UMAPATHI T, KOR AC, VENKETASUBRAMANIAN N, LIM CC, PANG BC, YEO TT ET al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol 2004; 251: 1227-1231. https://doi.org/10.1007/s00415-004-0519-8
NG WF, WONG SF, LAM A, MAK YF, YAO H, LEE KC et al. The placentas of patients with severe acute respiratory syndrome: a pathophysiological evaluation. Pathology 2006; 38: 210-218. https://doi.org/10.1080/00313020600696280
XIANG-HUA Y, LE-MIN W, AI-BIN L, ZHU G, RIQUAN L, XU-YOU Z et al. Severe acute respiratory syndrome and venous thromboembolism in multiple organs. Am J Respir Crit Care Med 2010; 182: 436-437. https://doi.org/10.1164/ajrccm.182.3.436
WONG RS, WU A, TO KF, LEE N, LAM CW, WONG CK et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 2003; 326: 1358-1362. https://doi.org/10.1136/bmj.326.7403.1358
CHEN SY, SU CP, MA MH, CHIANG WC, HSU CY, KO PC et al. Predictive model of diagnosing probable cases of severe acute respiratory syndrome in febrile patients with exposure risk. Ann Emerg Med 2004; 43: 1-5. https://doi.org/10.1016/s0196-0644(03)00817-5
LEE N, HUI D, WU A, CHAN P, CAMERON P, JOYNT GM et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 986-994.
NG LF, HIBBERD ML, OOI EE, TANG KF, NEO SY, TAN J et al. A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. BMC Infect Dis 2004; 4: 34. https://doi.org/10.1186/1471-2334-4-34
GRALINSKI LE, BARIC RS. Molecular pathology of emerging coronavirus infections. J Pathol 2015; 235: 185-195. https://doi.org/10.1002/path.4454
ASSIRI A, AL-TAWFIQ JA, AL-RABEEAH AA, AL-RABIAH FA, AL-HAJJAR S, AL-BARRAK A et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13: 752-761. https://doi.org/10.1016/s1473-3099(13)70204-4
HWANG SM, NA BJ, JUNG Y, LIM HS, SEO JE, PARK SA et al. Clinical and laboratory findings of Middle East respiratory syndrome coronavirus infection. Jpn J Infect Dis 2019; 72: 160-167. https://doi.org/10.7883/yoken.jjid.2018.187
SINGH SK. Middle East respiratory syndrome virus pathogenesis. Semin Respir Crit Care Med 2016; 37: 572-577. https://doi.org/10.1055/s-0036-1584796
SAAD M, OMRANI AS, BAIG K, BAHLOUL A, ELZEIN F, MATIN MA et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 2014; 29: 301-306. https://doi.org/10.1016/j.ijid.2014.09.003
LI K, WOHLFORD-LENANE C, PERLMAN S, ZHAO J, JEWELL AK, REZNIKOV LR et al. middle east respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J Infect Dis 2016; 213: 712-722. https://doi.org/10.1093/infdis/jiv499
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2020 Anales del Sistema Sanitario de Navarra
Esta obra está bajo una licencia internacional Creative Commons Atribución-CompartirIgual 4.0.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
